Aug 22, 2024 / 07:00AM GMT
Antti Vuolanto - Herantis Pharma Oyj - Chief Executive Officer
Good morning. My name is Antti Vuolanto, I'm the CEO of Herantis Pharma and welcome to the first half report webinar for Herantis Pharma. So first, the necessary forward-looking statements. And let's go then into the company update, followed by the first half report highlights.
So Herantis Pharma, we are a clinical-stage public company and we develop disease-modifying therapies for Parkinsonâs disease and other neurodegenerative diseases. And our lead asset is HER-096 that is a peptide that mimics a CDNF protein and seed enough protein has been earlier shown to break the cycle of Parkinson's disease pathogenesis.
And we have last year completed the Phase 1a clinical study with HER-096 demonstrating brain penetration and good safety profile after subcutaneous administration. What is very specific for Herantis and HER-096 is that we actually have signs of efficacy already in clinical settings with the mother molecule as we call it, the CDNF in Phase 1 clinical study with fairly advanced Parkinson's patients.
And this
Half Year 2024 Herantis Pharma Oyj Earnings Call Transcript
Aug 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers